SCHEMBL20166094

SCHEMBL20166094

CC(C)(C)OC(=O)N1CC(Oc2c(F)ccc(F)c2F)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 4/20 0.42
GPR119 Q8TDV5 3/20 0.42
RORC P51449 1/20 0.41
CACNB4 O00305 1/20 0.40
CACNA1A O00555 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNG3 O60359 1/20 0.40
CACNA1F O60840 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNB3 P54284 1/20 0.40
CACNA2D1 P54289 1/20 0.40
CACNG7 P62955 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNA1D Q01668 1/20 0.40
CACNB1 Q02641 1/20 0.40
CACNG1 Q06432 1/20 0.40
CACNB2 Q08289 1/20 0.40
CACNA1S Q13698 1/20 0.40
CACNA1C Q13936 1/20 0.40
CACNA1E Q15878 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22817815 0.88 USP30 (0.43) USP30GPR119RORCCACNB4CACNA1A
SCHEMBL22817814 0.85 GPR119 (0.49) USP30GPR119RORCCACNB4CACNA1A
SCHEMBL22817807 0.84 NR1H2 (0.44) USP30GPR119RORCNR1H2NAMPT
SCHEMBL22266021 0.83 GPR119 (0.55) USP30GPR119CACNB4CACNA1ACACNA1G
SCHEMBL31312460 0.83 GPR119 (0.55) USP30GPR119CACNB4CACNA1ACACNA1G
SCHEMBL20165945 0.82 USP30 (0.43) USP30GPR119RORCCACNB4CACNA1A
SCHEMBL20165809 0.82 SLC6A2 (0.47) USP30GPR119RORCCACNB4CACNA1A
SCHEMBL20439309 0.80 USP30 (0.52) USP30GPR119RORCCACNB4CACNA1A
SCHEMBL20165925 0.80 CES2 (0.35) USP30
SCHEMBL20165784 0.80 GPR119 (0.49) USP30GPR119RORCCACNB4CACNA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541784-B1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) 2023-09-13 EP disclosed
CN-109963834-B Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission 综合研究实验室瑞典股份公司 2023-04-14 CN disclosed
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2020-12-29 US disclosed
EP-3541784-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Integrative Research Laboratories Sweden AB (SE) 2019-09-25 EP disclosed
WO-2018091687-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission SLC18A1, CHRM1, CHRM2 USP30 1863/4885GPR119 55/4885RORC 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.